|
|
SFX by Ex Libris Inc. |
Contains information about title and source of a journal
Naslov: |
Dupilumab provides sustained effectiveness on patient-reported outcomes and favorable safety in patients with moderate-to-severe atopic dermatitis: Up to 5-year results from the daily practice BioDay registry |
Vir: |
|
|
|
List of services to meet your request
Contains list of services for current record
|
|
|
© 2024 SFX by Ex Libris Inc. | Cookie Policy
CrossRef Omogočeno
|